| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning | 12 | 2016 | 48 | 2.740 |
Why?
|
| Brain Ischemia | 14 | 2020 | 179 | 2.590 |
Why?
|
| Brain | 8 | 2015 | 1268 | 1.270 |
Why?
|
| Ubiquitin | 4 | 2009 | 76 | 1.210 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2009 | 109 | 1.180 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2013 | 146 | 1.120 |
Why?
|
| Ischemia | 4 | 2022 | 45 | 0.930 |
Why?
|
| N-Methylaspartate | 1 | 2022 | 55 | 0.870 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 131 | 0.830 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2011 | 229 | 0.730 |
Why?
|
| Stroke | 8 | 2020 | 274 | 0.730 |
Why?
|
| Membrane Proteins | 5 | 2011 | 486 | 0.640 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 4 | 0.630 |
Why?
|
| Rats | 18 | 2022 | 3261 | 0.610 |
Why?
|
| Neurons | 10 | 2020 | 1130 | 0.600 |
Why?
|
| Genomics | 3 | 2017 | 201 | 0.570 |
Why?
|
| Hypertension | 1 | 2022 | 770 | 0.540 |
Why?
|
| RNA | 1 | 2017 | 234 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 592 | 0.530 |
Why?
|
| Animals | 31 | 2022 | 14307 | 0.520 |
Why?
|
| Yttrium Radioisotopes | 1 | 2013 | 7 | 0.480 |
Why?
|
| Doxorubicin | 1 | 2013 | 80 | 0.460 |
Why?
|
| Hippocampus | 8 | 2012 | 546 | 0.450 |
Why?
|
| Cells, Cultured | 9 | 2011 | 1442 | 0.430 |
Why?
|
| Proteins | 4 | 2011 | 352 | 0.410 |
Why?
|
| Apoptosis | 6 | 2007 | 1317 | 0.410 |
Why?
|
| Epilepsy | 3 | 2007 | 41 | 0.410 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 147 | 0.400 |
Why?
|
| Ubiquitination | 1 | 2011 | 54 | 0.400 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 195 | 0.390 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 152 | 0.380 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 69 | 0.380 |
Why?
|
| Fibroblasts | 1 | 2011 | 252 | 0.350 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 12 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 139 | 0.340 |
Why?
|
| Neuroprotective Agents | 4 | 2018 | 231 | 0.330 |
Why?
|
| Mice | 15 | 2021 | 5668 | 0.310 |
Why?
|
| Down-Regulation | 1 | 2009 | 420 | 0.300 |
Why?
|
| Synapses | 1 | 2008 | 173 | 0.290 |
Why?
|
| Parkinson Disease | 1 | 2007 | 167 | 0.280 |
Why?
|
| Cell Death | 7 | 2008 | 260 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2016 | 1534 | 0.270 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 10 | 0.270 |
Why?
|
| Caspases | 2 | 2002 | 132 | 0.260 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 50 | 0.260 |
Why?
|
| Humans | 19 | 2022 | 34853 | 0.250 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2012 | 16 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 97 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 94 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2021 | 386 | 0.220 |
Why?
|
| Glycine | 1 | 2022 | 44 | 0.220 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 33 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2004 | 160 | 0.220 |
Why?
|
| Brain Diseases | 1 | 2002 | 33 | 0.210 |
Why?
|
| Actins | 1 | 2022 | 142 | 0.210 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 165 | 0.210 |
Why?
|
| Male | 19 | 2021 | 18870 | 0.200 |
Why?
|
| Neuroglia | 1 | 2002 | 117 | 0.200 |
Why?
|
| DNA Repair | 2 | 2018 | 181 | 0.200 |
Why?
|
| Analysis of Variance | 4 | 2012 | 528 | 0.190 |
Why?
|
| Dynamins | 1 | 2020 | 15 | 0.190 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2006 | 126 | 0.190 |
Why?
|
| Phosphorylation | 4 | 2020 | 878 | 0.190 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 18 | 0.180 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 15 | 0.180 |
Why?
|
| Cycloheximide | 3 | 2009 | 30 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 20 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 600 | 0.170 |
Why?
|
| Time Factors | 3 | 2009 | 1681 | 0.170 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 968 | 0.170 |
Why?
|
| Cohort Studies | 1 | 2022 | 1422 | 0.170 |
Why?
|
| Child, Preschool | 1 | 2022 | 1318 | 0.170 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 53 | 0.170 |
Why?
|
| Status Epilepticus | 2 | 2008 | 11 | 0.160 |
Why?
|
| Blotting, Western | 5 | 2012 | 834 | 0.160 |
Why?
|
| Military Medicine | 1 | 2017 | 9 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2019 | 1802 | 0.150 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2009 | 20 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2009 | 323 | 0.150 |
Why?
|
| DNA, Complementary | 1 | 2017 | 175 | 0.150 |
Why?
|
| Glucose | 2 | 2009 | 217 | 0.150 |
Why?
|
| Military Personnel | 1 | 2017 | 67 | 0.150 |
Why?
|
| Cerebral Cortex | 2 | 2009 | 274 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2012 | 200 | 0.140 |
Why?
|
| Brain Injuries | 1 | 2017 | 104 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 555 | 0.140 |
Why?
|
| Middle Aged | 5 | 2021 | 9642 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1349 | 0.140 |
Why?
|
| Nuclear Proteins | 5 | 2004 | 287 | 0.140 |
Why?
|
| Carrier Proteins | 3 | 2008 | 287 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 184 | 0.130 |
Why?
|
| Sleep | 1 | 2016 | 122 | 0.130 |
Why?
|
| Seizures | 3 | 2007 | 67 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 628 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2561 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 396 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 859 | 0.130 |
Why?
|
| Risk Factors | 1 | 2022 | 3414 | 0.130 |
Why?
|
| Electroencephalography | 4 | 2016 | 108 | 0.120 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2004 | 40 | 0.120 |
Why?
|
| Capsules | 1 | 2013 | 24 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 57 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 55 | 0.120 |
Why?
|
| United States | 1 | 2022 | 3894 | 0.110 |
Why?
|
| Sclerosis | 1 | 2012 | 6 | 0.110 |
Why?
|
| Killifishes | 1 | 2012 | 2 | 0.110 |
Why?
|
| Ribonuclease III | 1 | 2012 | 10 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 11 | 0.110 |
Why?
|
| Autophagy | 1 | 2013 | 111 | 0.110 |
Why?
|
| Mitochondria | 3 | 2020 | 454 | 0.110 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 57 | 0.110 |
Why?
|
| Calcium | 2 | 2020 | 445 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2017 | 1961 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 106 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 39 | 0.100 |
Why?
|
| DNA Glycosylases | 2 | 2018 | 16 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 794 | 0.100 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2020 | 76 | 0.100 |
Why?
|
| Carcinogens | 1 | 2011 | 117 | 0.090 |
Why?
|
| Microarray Analysis | 2 | 2008 | 61 | 0.090 |
Why?
|
| Female | 7 | 2021 | 19873 | 0.090 |
Why?
|
| Adult | 5 | 2021 | 11034 | 0.090 |
Why?
|
| Caspase 7 | 3 | 2007 | 16 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2006 | 21 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 17 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 59 | 0.090 |
Why?
|
| Cytoprotection | 1 | 2008 | 32 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2020 | 897 | 0.080 |
Why?
|
| Protein Kinases | 2 | 2007 | 91 | 0.080 |
Why?
|
| Models, Biological | 2 | 2009 | 642 | 0.080 |
Why?
|
| Vitamin A | 1 | 2008 | 87 | 0.080 |
Why?
|
| Carbocyanines | 1 | 2008 | 14 | 0.080 |
Why?
|
| Protein Binding | 1 | 2011 | 913 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2007 | 8 | 0.080 |
Why?
|
| Hypoxia, Brain | 1 | 2007 | 7 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 64 | 0.080 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 1300 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 2 | 2007 | 71 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 325 | 0.080 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 214 | 0.080 |
Why?
|
| Membrane Potentials | 1 | 2008 | 213 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 90 | 0.080 |
Why?
|
| Dizocilpine Maleate | 1 | 2007 | 45 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 81 | 0.070 |
Why?
|
| Mutation | 1 | 2011 | 1023 | 0.070 |
Why?
|
| Nerve Degeneration | 2 | 2004 | 101 | 0.070 |
Why?
|
| Leupeptins | 1 | 2006 | 11 | 0.070 |
Why?
|
| Propidium | 1 | 2006 | 18 | 0.070 |
Why?
|
| Butadienes | 1 | 2006 | 30 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 38 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2005 | 245 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 185 | 0.070 |
Why?
|
| Kainic Acid | 4 | 2008 | 47 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 54 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 102 | 0.070 |
Why?
|
| Caspase 6 | 2 | 2002 | 4 | 0.070 |
Why?
|
| Lamins | 2 | 2002 | 5 | 0.070 |
Why?
|
| Nitriles | 1 | 2006 | 66 | 0.070 |
Why?
|
| Lamin Type A | 2 | 2002 | 13 | 0.070 |
Why?
|
| Staurosporine | 2 | 2002 | 35 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 170 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 200 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 52 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 35 | 0.060 |
Why?
|
| Glioma | 2 | 2002 | 76 | 0.060 |
Why?
|
| Reperfusion | 2 | 2018 | 15 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2005 | 97 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2004 | 22 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 480 | 0.060 |
Why?
|
| Phenotype | 1 | 2007 | 650 | 0.060 |
Why?
|
| Hibernation | 1 | 2003 | 7 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2003 | 20 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 32 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 20 | 0.060 |
Why?
|
| Pyramidal Cells | 1 | 2003 | 60 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2003 | 116 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 1530 | 0.050 |
Why?
|
| Ferrets | 1 | 2021 | 12 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2002 | 194 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 138 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 66 | 0.050 |
Why?
|
| Cricetinae | 1 | 2021 | 217 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 639 | 0.050 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2021 | 148 | 0.050 |
Why?
|
| Superoxides | 1 | 2020 | 51 | 0.050 |
Why?
|
| Systems Theory | 1 | 2019 | 3 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 338 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 79 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 302 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 188 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 653 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 17 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 115 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 172 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 580 | 0.040 |
Why?
|
| Inflammation | 1 | 2021 | 577 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2333 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2006 | 13 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 298 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2019 | 1152 | 0.030 |
Why?
|
| Antibodies | 2 | 2007 | 135 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 781 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2128 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 19 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 42 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2004 | 351 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2004 | 490 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 392 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 6448 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 275 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 57 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2008 | 21 | 0.020 |
Why?
|
| Ion Channels | 1 | 2008 | 69 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 162 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2008 | 99 | 0.020 |
Why?
|
| Vitamins | 1 | 2008 | 91 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 16 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 45 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 78 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 130 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 91 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 70 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 117 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 115 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 37 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 19 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2006 | 31 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 72 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 984 | 0.020 |
Why?
|
| Indoles | 1 | 2006 | 154 | 0.020 |
Why?
|
| Denervation | 1 | 2004 | 26 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2003 | 5 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2004 | 75 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 74 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 39 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2003 | 16 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2003 | 19 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 16 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2003 | 4 | 0.010 |
Why?
|
| DNA Ligases | 1 | 2003 | 11 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2003 | 18 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 72 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2004 | 135 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2003 | 42 | 0.010 |
Why?
|
| Endodeoxyribonucleases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 286 | 0.010 |
Why?
|
| Convulsants | 1 | 2002 | 5 | 0.010 |
Why?
|
| Diazepam | 1 | 2002 | 10 | 0.010 |
Why?
|
| GABA Agonists | 1 | 2002 | 21 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 48 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2002 | 72 | 0.010 |
Why?
|
| Microinjections | 1 | 2002 | 55 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 430 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 197 | 0.010 |
Why?
|
| Amygdala | 1 | 2002 | 110 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 423 | 0.010 |
Why?
|
| Hela Cells | 1 | 2002 | 344 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 818 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 5035 | 0.010 |
Why?
|